#None #Securities Investigation #Ardelyx #ARDX

Ardelyx Stock Decline Sparks Securities Investigation

On August 7, 2026, Ardelyx Inc. (NASDAQ: ARDX) experienced a drastic decline in its stock value, closing at $4.00, which reflects a staggering drop of 17.86% within a single trading session. This downturn emerged after the company's management revised its revenue forecast for the 2026 financial year, cutting the anticipated IBSRELA revenue by up to $80 million. This abrupt shift has raised concerns among shareholders, prompting a securities investigation led by the reputable law firm Levi & Korsinsky.

Revenue Guidance Change

Originally, Ardelyx had set a revenue target of $410 million to $430 million for IBSRELA on April 30, 2026. However, in a shocking turn of events, on August 6, 2026, the company altered its guidance downwards to a revised range of $350 million to $370 million. This revision stemmed from increased challenges related to payer utilization management, characterized by stricter prior authorizations and additional procedural steps that have hindered new patient enrollments. According to management, the extent of these restrictions was unexpected and significantly impacted operations.

The situation escalated as the company also withdrew its long-term revenue target of $750 million for XPHOZAH, further alarmed investors and signaling potential long-term setbacks. The abruptness of these changes not only shocked the market but also raised questions about the transparency of the company's previous disclosures about its operational challenges.

Legal Rights for Shareholders

In light of these developments, shareholders who purchased ARDX stock and incurred losses are encouraged to consult with legal professionals to explore their rights. The investigation seeks to determine whether Ardelyx adequately disclosed the operational risks and challenges surrounding the changes in revenue guidance. Affected investors can participate in the inquiry without any upfront costs, and they do not need to hold their shares to be eligible for compensation.

If you are among the shareholders seeking clarity and potential recovery for your losses, it’s advisable to gather your brokerage records detailing purchase dates, quantities held, and prices paid, as these will be essential for reviewing potential claims.

Frequently Asked Questions

Q1: What statements are under investigation?
The inquiry centers on whether Ardelyx misrepresented its 2026 revenue outlook and did not properly communicate the payer management difficulties impacting new patient registrations.

Q2: What happened to ARDX stock?
On August 7, 2026, ARDX stocks plunged 17.86%, closing at $4.00, following the revision of the revenue guidance and withdrawal of its long-term targets.

Q3: Who can participate in the investigation?
Any investors who bought ARDX shares and faced financial losses are eligible to participate in the investigation.

Q4: What should concerned investors do?
Investors should collect documentation showing their shares purchased, as well as any transactions made afterward, to assist in the legal process.

Conclusion

As the investigation heats up, the potential implications for Ardelyx and its investors could be significant. Stakeholders and those who haven't yet spoken with legal professionals are encouraged to act promptly. With such a substantial financial shift, remaining vigilant during this turbulent timeframe is crucial for interested parties. Further inquiries can be directed to Levi & Korsinsky, LLP, for those seeking more information regarding their potential claims and the ongoing investigation.

For assistance, contact Joseph E. Levi, Esq. at (212) 363-7500 or visit Levi & Korsinsky's website.